Jezper / Shutterstock.com
In-house counsel face daily challenges when managing and maintaining their IP portfolios. LSIPR asked two in-house counsel for the biggest challenges they face when managing and maintaining their IP portfolios. Here are the five things we learned.
1) Different patentability standards
In some countries it’s very difficult, if not impossible, to get claims that include ranges of sequence identity, warns Kamrin MacKnight, chief patent counsel at protein engineering company Codexis.
“We’re stuck with claims that cover only a specific sequence. That makes it much easier for competitors to design around our patents, as all they have to do is change one amino acid,” says MacKnight.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
IP portfolios, patentability, amino acid, US Supreme Court, biotech, DNA, IP counsel, European Patent Office, USPTO, IPRs, inventions, litigation